润都股份困局：高管密集减持与创新药“远水难解近渴”

Core Viewpoint - Rundu Co., Ltd. is expected to report a net loss attributable to shareholders of between 60 million to 78 million yuan for the year 2025, marking its first annual loss since its listing in 2018. The company faces multiple challenges between transformation and survival, with key innovations in drug review stages contrasted by significant executive sell-offs and declining core business performance [1][8]. Group 1: Executive Sell-offs and Performance Expectations - Since December 2025, major shareholders and executives, including the actual controller Li Xi, have announced plans to reduce their holdings, with Li Xi planning to sell up to 3% of total shares, estimated to raise nearly 130 million yuan. As of December 14, 2025, his pledged shares reached 73.53%, accounting for 20.65% of the total shares [2][9]. - Li Xi had previously completed a round of sell-off in November 2025, cashing out over 87 million yuan. Other executives, including the general manager Liu Jie and deputy general manager You Chunyan, also planned to sell shares citing personal financial needs [2][9]. - The timing of these sell-offs coincides with a critical period for the review of innovative drugs, contrasting sharply with market optimism regarding drug approvals, thus signaling caution about short-term prospects [2][9]. Group 2: Core Business Pressures and Impact of Centralized Procurement - The anticipated losses are not without precedent, as Rundu Co., Ltd. reported a 40.38% year-on-year decline in net profit in 2024, with a further 8.22% revenue drop in the first half of 2025, leading to a shift from profit to loss. The gross profit margin also fell by 12.23 percentage points [3][10]. - The core formulation business has been significantly impacted by centralized procurement, particularly the revenue from Rabeprazole Sodium Enteric-Coated Capsules, which saw a 13.74% decline in the first half of 2025, with a gross margin drop of 9.66 percentage points. The raw material business's gross margin plummeted from 17.37% to 6.24%, severely constricting profit margins [3][10]. - Although the nicotine business experienced sales growth, it has not yet made a significant impact on overall performance. The intermediate business has further dragged down annual performance due to price declines and asset disposal losses [3][10]. Group 3: Risks Behind Innovative Drug Expectations - The injection of dextromethorphan hydrochloride is seen as a key to Rundu Co., Ltd.'s transition to innovative drugs, potentially becoming the first domestic drug for myocardial perfusion imaging, filling a market gap [4][11]. - However, this innovative drug faces three major challenges: - Approval remains uncertain, with a 2024 approval rate for Class 1 innovative drugs at 86.21%, indicating that not all will be approved [5][12]. - Intense market competition exists, as current drugs like adenosine and dipyridamole are already included in medical insurance, creating pricing challenges for new products [5][12]. - The market education cycle is lengthy, with only a 5% penetration rate for MPI in China, requiring extensive promotion and training for doctors, making rapid market uptake difficult [5][12]. - Even if approved in the first half of 2026, the drug will require time for hospital entry and promotion, which will not immediately offset existing business losses [6][12]. - Additionally, the company's generic drug pipeline, including sacubitril valsartan tablets, faces industry-wide pressures from falling generic drug prices [7][13].